Last reviewed · How we verify
Myfortic plus low-dose steroid
Myfortic (mycophenolate sodium) combined with low-dose corticosteroids suppresses T and B lymphocyte proliferation to prevent organ rejection, while the steroid provides additional anti-inflammatory effects.
Myfortic (mycophenolate sodium) combined with low-dose corticosteroids suppresses T and B lymphocyte proliferation to prevent organ rejection in transplant recipients. Used for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.
At a glance
| Generic name | Myfortic plus low-dose steroid |
|---|---|
| Also known as | Mycophenolate sodium |
| Sponsor | The University of Hong Kong |
| Drug class | Immunosuppressant (inosine monophosphate dehydrogenase inhibitor) |
| Target | Inosine monophosphate dehydrogenase (IMPDH), type II |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Mycophenolate sodium is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme critical for guanine nucleotide synthesis in lymphocytes. This preferentially depletes guanine nucleotides in T and B cells, inhibiting their proliferation. The addition of low-dose corticosteroids enhances immunosuppression through glucocorticoid receptor-mediated suppression of cytokine production and immune cell activation.
Approved indications
- Organ transplant rejection prevention (renal, cardiac, hepatic transplantation)
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, abdominal pain)
- Infection (bacterial, viral, fungal)
- Leukopenia
- Anemia
- Hypertension
- Hyperglycemia
- Tremor, headache
Key clinical trials
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy (PHASE3)
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) (PHASE3)
- A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf (NA)
- Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (PHASE2)
- Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts (PHASE3)
- Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation (PHASE4)
- Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Myfortic plus low-dose steroid CI brief — competitive landscape report
- Myfortic plus low-dose steroid updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI